N-cadherin (cadherin-2 [CDH2]) is widely known as the promoter of prostate cancer (PCa) invasion and castration resistance. However, the biological mechanism of N-cadherin in PCa progression is unclear. In this study, we overexpressed N-cadherin in LNCaP cells and downregulated N-cadherin in PC3 cells by lentiviral transduction. Then, differentially expressed genes (DEGs) and dysregulated biological functions were investigated through RNA sequencing (RNA-seq) analyses. We found 13 long noncoding RNA (lncRNA) transcripts, 72 messenger RNA (mRNA) transcripts, and 3 integrated genes were dysregulated by N-cadherin. In the disease enrichment, bone cancer, and neurodegenerative and nervous system diseases were associated with N-cadherin in the circular RNA (circRNA; PC3 versus [vs.,/] LNCaP [PC3/LNCaP] comparison) and DEG analysis (LNCaP_oe_CDH2 vs. LNCaP_oe_NC [LNCaP_oe_CDH2/NC] comparison). Epigenetic reprogramming, such as nucleic acid binding, and chromatin and histone modifications, was enriched in Gene Ontology (GO) analysis (DEGs in LNCaP_oe_CDH2/NC and PC3_sh_NC/CDH2, and host genes of circRNA in PC3/LNCaP). Transcriptional misregulation in cancer, post-translational protein modification, gene expression, and generic transcription pathways were dysregulated in the pathway enrichment analysis (host genes of circRNA in PC3/LNCaP, and DEGs in LNCaP_oe_CDH2/NC and PC3_sh_NC/CDH2). Verifying DEGs through TCGA-PRAD dataset revealed six oncogenes (ARHGEF1, GRAMD1A, GTF2H4, MAPK8IP3, POLD1, and PTBP1) that were commonly upregulated by N-cadherin and in advanced PCa stages. In summary, we identified several oncogenes and biological functions associated with N-cadherin expression in PCa cells. N-cadherin may trigger epigenetic reprogramming in PCa cells to promote tumor progression.
Get full access to this article
View all access options for this article.
References
1.
AndersS., and HuberW. (2010). Differential expression analysis for sequence count data. Genome Biol 11,R106.
2.
BoX., and WangS. (2005). TargetFinder: a software for antisense oligonucleotide target site selection based on MAST and secondary structures of target mRNA. Bioinformatics, 21, 1401–1402.
3.
BrownJ., PirrungM., and MccueL.A. (2017). FQC Dashboard: integrates FastQC results into a web-based, interactive, and extensible FASTQ quality control tool. Bioinformatics, 33, 3137–3139.
4.
BuchananG., CraftP.S., YangM., CheongA., PrescottJ., JiaL., et al. (2004). PC-3 cells with enhanced androgen receptor signaling: a model for clonal selection in prostate cancer. Prostate, 60, 352–366.
5.
CaiQ., ChenY., ZhangD., PanJ., XieZ., MaS., et al. (2020). Loss of epithelial AR increase castration resistant stem-like prostate cancer cells and promotes cancer metastasis via TGF-β1/EMT pathway. Transl Androl Urol, 9, 1013–1027.
6.
ChangY.T., LinT.P., CampbellM., PanC.C., LeeS.H., LeeH.C., et al. (2017). REST is a crucial regulator for acquiring EMT-like and stemness phenotypes in hormone-refractory prostate cancer. Sci Rep 7,42795.
7.
ChangY.T., LinT.P., TangJ.T., CampbellM., LuoY.L., LuS.Y., et al. (2018). HOTAIR is a REST-regulated lncRNA that promotes neuroendocrine differentiation in castration resistant prostate cancer. Cancer Lett, 433, 43–52.
8.
ChenJ., LiL., YangZ., LuoJ., YehS., and ChangC. (2017a). Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression. Cancer Lett, 408, 155–163.
9.
ChenW.Y., TsaiY.C., SiuM.K., YehH.L., ChenC.L., YinJ.J., et al. (2017b). Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis. Oncogene, 36, 6213–6224.
10.
CuiY., and YamadaS. (2013). N-cadherin dependent collective cell invasion of prostate cancer cells is regulated by the N-terminus of α-catenin. PLoS One 8,e55069.
11.
DaiM., ThompsonR.C., MaherC., Contreras-GalindoR., KaplanM.H., MarkovitzD.M., et al. (2010). NGSQC: cross-platform quality analysis pipeline for deep sequencing data. BMC Genomics 11 Suppl 4,S7.
12.
DeekM.P., Van der EeckenK., PhillipsR., ParikhN.R., Isaacsson VelhoP., LotanT.L., et al. (2021). The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited. Eur Urol, 80, 632–640.
13.
EggenerS.E., ScardinoP.T., WalshP.C., HanM., PartinA.W., TrockB.J., et al. (2011). Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol, 185, 869–875.
14.
FengY., YangY., ZhaoX., FanY., ZhouL., RongJ., et al. (2019). Circular RNA circ0005276 promotes the proliferation and migration of prostate cancer cells by interacting with FUS to transcriptionally activate XIAP. Cell Death Dis 10,792.
15.
FinnR.D., ClementsJ., and EddyS.R. (2011). HMMER web server: interactive sequence similarity searching. Nucleic Acids Res, 39, W29–W37.
16.
Flores-MoralesA., BergmannT.B., LavalleeC., BatthT.S., LinD., LerdrupM., et al. (2019). Proteogenomic characterization of patient-derived xenografts highlights the role of REST in neuroendocrine differentiation of castration-resistant prostate cancer. Clin Cancer Res, 25, 595–608.
17.
GravdalK., HalvorsenO.J., HaukaasS.A., and AkslenL.A. (2007). A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res, 13, 7003–7011.
18.
GustK.M., HoferM.D., PernerS.R., KimR., ChinnaiyanA.M., VaramballyS., et al. (2009). RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. Neoplasia, 11, 956–963.
19.
HanB., ChaoJ., and YaoH. (2018). Circular RNA and its mechanisms in disease: from the bench to the clinic. Pharmacol Ther, 187, 31–44.
20.
HuangS.P., ChenL.C., ChenY.T., LeeC.H., HuangC.Y., YuC.C., et al. (2021). PTBP1 genetic variants affect the clinical response to androgen-deprivation therapy in patients with prostate cancer. Cancer Genomics Proteomics, 18, 325–334.
21.
HuoC., KaoY.H., and ChuuC.P. (2015). Androgen receptor inhibits epithelial-mesenchymal transition, migration, and invasion of PC-3 prostate cancer cells. Cancer Lett, 369, 103–111.
22.
HurovK., LahdenrantaJ., UpadhyayaP., HainesE., CohenH., RepashE., et al. (2021). BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) induces tumor localized CD137 agonism. J Immunother Cancer 9,e002883.
23.
JaggiM., NazemiT., AbrahamsN.A., BakerJ.J., GalichA., SmithL.M., et al. (2006). N-cadherin switching occurs in high Gleason grade prostate cancer. Prostate, 66, 193–199.
24.
JeckW.R., SorrentinoJ.A., WangK., SlevinM.K., BurdC.E., LiuJ., et al. (2013). Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA, 19, 141–157.
25.
JennbackenK., TesanT., WangW., GustavssonH., DamberJ.E., and WelénK. (2010). N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocr Relat Cancer, 17, 469–479.
26.
JiaL., WuD., WangY., YouW., WangZ., XiaoL., et al. (2018). Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription. Oncogene, 37, 3340–3355.
27.
KaighnM.E., NarayanK.S., OhnukiY., LechnerJ.F., and JonesL.W. (1979). Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol, 17, 16–23.
28.
KimD., PerteaG., TrapnellC., PimentelH., KelleyR., and SalzbergS.L. (2013). TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 14,R36.
29.
KongL., ZhangY., YeZ.Q., LiuX.Q., ZhaoS.Q., WeiL., et al. (2007). CPC: assess the protein-coding potential of transcripts using sequence features and support vector machine. Nucleic Acids Res, 35, W345–W349.
30.
KozminskiM.A., TomlinsS., ColeA., SinghalU., LuL., SkolarusT.A., et al. (2016). Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. Urol Oncol, 34, 415.e1–415.e6.
31.
KrzywinskiM., ScheinJ., BirolI., ConnorsJ., GascoyneR., HorsmanD., et al. (2009). Circos: an information aesthetic for comparative genomics. Genome Res, 19, 1639–1645.
32.
LabernadieA., KatoT., BruguésA., Serra-PicamalX., DerzsiS., ArwertE., et al. (2017). A mechanically active heterotypic E-cadherin/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion. Nat Cell Biol, 19, 224–237.
33.
LiL., WeiH., ZhangY.W., ZhaoS., CheG., WangY., et al. (2021). Differential expression of long non-coding RNAs as diagnostic markers for lung cancer and other malignant tumors. Aging (Albany NY), 13, 23842–23867.
34.
LiX.N., WangZ.J., YeC.X., ZhaoB.C., LiZ.L., and YangY. (2018). RNA sequencing reveals the expression profiles of circRNA and indicates that circDDX17 acts as a tumor suppressor in colorectal cancer. J Exp Clin Cancer Res 37,325.
35.
LiuJ., LiuT., WangX., and HeA. (2017). Circles reshaping the RNA world: from waste to treasure. Mol Cancer 16,58.
36.
MaoS., ZhangW., YangF., GuoY., WangH., WuY., et al. (2021). Hsa_circ_0004296 inhibits metastasis of prostate cancer by interacting with EIF4A3 to prevent nuclear export of ETS1 mRNA. J Exp Clin Cancer Res 40,336.
37.
MendirattaP., MostaghelE., GuinneyJ., TewariA.K., PorrelloA., BarryW.T., et al. (2009). Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol, 27, 2022–2029.
38.
MiaoL., YangL., LiR., RodriguesD.N., CrespoM., HsiehJ.T., et al. (2017). Disrupting androgen receptor signaling induces Snail-mediated epithelial-mesenchymal plasticity in prostate cancer. Cancer Res, 77, 3101–3112.
39.
NallaA.K., EstesN., PatelJ., and RaoJ.S. (2011). N-cadherin mediates angiogenesis by regulating monocyte chemoattractant protein-1 expression via PI3K/Akt signaling in prostate cancer cells. Exp Cell Res, 317, 2512–2521.
40.
NiuY., AltuwaijriS., LaiK.P., WuC.T., RickeW.A., MessingE.M., et al. (2008a). Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A, 105, 12182–12187.
41.
NiuY., AltuwaijriS., YehS., LaiK.P., YuS., ChuangK.H., et al. (2008b). Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci U S A, 105, 12188–12193.
42.
PerteaM., PerteaG.M., AntonescuC.M., ChangT.C., MendellJ.T., and SalzbergS.L. (2015). StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol, 33, 290–295.
QuanY., CuiY., WahafuW., LiuY., PingH., and ZhangX. (2020). MLL5α activates AR/NDRG1 signaling to suppress prostate cancer progression. Am J Cancer Res, 10, 1608–1629.
45.
QuanY., ZhangX., ButlerW., DuZ., WangM., LiuY., et al. (2021). The role of N-cadherin/c-Jun/NDRG1 axis in the progression of prostate cancer. Int J Biol Sci, 17, 3288–3304.
46.
QuanY., ZhangX., and PingH. (2022). Construction of a risk prediction model using m6A RNA methylation regulators in prostate cancer: comprehensive bioinformatic analysis and histological validation. Cancer Cell Int 22,33.
47.
RosatiM., RocchiM., StorlazziC.T., and GrimaldiG. (2001). Assignment to chromosome 12q24.33, gene organization and splicing of the human KRAB/FPB containing zinc finger gene ZNF84. Cytogenet Cell Genet, 94, 127–130.
48.
SamantaD., and AlmoS.C. (2015). Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificity. Cell Mol Life Sci, 72, 645–658.
49.
SchoenherrC.J., and AndersonD.J. (1995). The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes. Science, 267, 1360–1363.
50.
ShangQ., YangZ., JiaR., and GeS. (2019). The novel roles of circRNAs in human cancer. Mol Cancer 18,6.
51.
ShenC.P., JanL.Y., and JanY.N. (1997). Miranda is required for the asymmetric localization of Prospero during mitosis in Drosophila. Cell, 90, 449–458.
52.
SiegelR.L., MillerK.D., FuchsH.E., and JemalA. (2022). Cancer statistics, 2022. CA Cancer J Clin, 72, 7–33.
53.
Strzeszewska-PotyrałaA., StaniakK., Czarnecka-HerokJ., RafieeM.R., HerokM., MosieniakG., et al. (2021). Chromatin-directed proteomics identifies ZNF84 as a p53-independent regulator of p21 in genotoxic stress response. Cancers (Basel) 13,2115.
54.
SuG., MorrisJ.H., DemchakB., and BaderG.D. (2014). Biological network exploration with Cytoscape 3. Curr Protoc Bioinformatics, 47, 8.13.1–8.13.24.
55.
SunL., LuoH., BuD., ZhaoG., YuK., ZhangC., et al. (2013). Utilizing sequence intrinsic composition to classify protein-coding and long non-coding transcripts. Nucleic Acids Res 41,e166.
56.
SunY., WangB.E., LeongK.G., YueP., LiL., JhunjhunwalaS., et al. (2012). Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res, 72, 527–536.
57.
SvenssonC., CederJ., Iglesias-GatoD., ChuanY.C., PangS.T., BjartellA., et al. (2014). REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. Nucleic Acids Res, 42, 999–1015.
58.
TanG., and LenhardB. (2016). TFBSTools: an R/bioconductor package for transcription factor binding site analysis. Bioinformatics, 32, 1555–1556.
59.
TanakaH., KonoE., TranC.P., MiyazakiH., YamashiroJ., ShimomuraT., et al. (2010). Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med, 16, 1414–1420.
60.
TsaiY.C., ChenW.Y., Abou-KheirW., ZengT., YinJ.J., BahmadH., et al. (2018). Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating SPDEF and activating CCL2. Biochim Biophys Acta Mol Basis Dis, 1864, 1717–1727.
61.
VliegheD., SandelinA., De BleserP.J., VleminckxK., WassermanW.W., van RoyF., et al. (2006). A new generation of JASPAR, the open-access repository for transcription factor binding site profiles. Nucleic Acids Res, 34, D95–D97.
62.
WangM., RenD., GuoW., HuangS., WangZ., LiQ., et al. (2016). N-cadherin promotes epithelial-mesenchymal transition and cancer stem cell-like traits via ErbB signaling in prostate cancer cells. Int J Oncol, 48, 595–606.
63.
WuJ., MaoX., CaiT., LuoJ., and WeiL. (2006). KOBAS server: a web-based platform for automated annotation and pathway identification. Nucleic Acids Res, 34, W720–W724.
64.
XiaoL., TienJ.C., VoJ., TanM., ParoliaA., ZhangY., et al. (2018). Epigenetic reprogramming with antisense oligonucleotides enhances the effectiveness of androgen receptor inhibition in castration-resistant prostate cancer. Cancer Res, 78, 5731–5740.
65.
XieC., MaoX., HuangJ., DingY., WuJ., DongS., et al. (2011). KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res, 39, W316–W322.
66.
YangZ., QuC.B., ZhangY., ZhangW.F., WangD.D., GaoC.C., et al. (2019). Dysregulation of p53-RBM25-mediated circAMOTL1L biogenesis contributes to prostate cancer progression through the circAMOTL1L-miR-193a-5p-Pcdha pathway. Oncogene, 38, 2516–2532.
67.
YuE.Y., PetrylakD.P., O'DonnellP.H., LeeJ.L., van der HeijdenM.S., LoriotY., et al. (2021). Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. Lancet Oncol, 22, 872–882.
68.
ZhangX., ColemanI.M., BrownL.G., TrueL.D., KollathL., LucasJ.M., et al. (2015). SRRM4 expression and the loss of REST activity may promote the emergence of the neuroendocrine phenotype in castration-resistant prostate cancer. Clin Cancer Res, 21, 4698–4708.
69.
ZhangX.O., DongR., ZhangY., ZhangJ.L., LuoZ., ZhangJ., et al. (2016). Diverse alternative back-splicing and alternative splicing landscape of circular RNAs. Genome Res, 26, 1277–1287.
70.
ZhouX., LindsayH., and RobinsonM.D. (2014). Robustly detecting differential expression in RNA sequencing data using observation weights. Nucleic Acids Res 42,e91.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
